EP Patent

EP3431475A1 — Solid forms of a selective cdk4/6 inhibitor

Assigned to Pfizer Inc · Expires 2019-01-23 · 7y expired

What this patent protects

This invention relates to the crystalline free base of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (formula (I)) having improved properties, to pharmaceutical compositions and dosage forms comprising the free base, and to…

USPTO Abstract

This invention relates to the crystalline free base of 6-acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8H-pyrido[2,3-d]pyrimidin-7-one (formula (I)) having improved properties, to pharmaceutical compositions and dosage forms comprising the free base, and to methods for making and using such compounds, compositions and dosage forms in the treatment of cell proliferative diseases, such as cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP3431475A1
Jurisdiction
EP
Classification
—
Expires
2019-01-23
Drug substance claim
No
Drug product claim
No
Assignee
Pfizer Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.